Login to Your Account

Other News To Note

Friday, June 24, 2011
Sirnaomic Inc., of Gaithersburg, Md., signed a partnership agreement with Guangdong Zhongsheng Pharmaceutical Co. Ltd., of Dongguan City, China, to develop small interfering RNA for diabetic retinopathy and age-related macular degeneration. The partnership will focus on clinical development and commercialization of STP601, a Sirnaomics compound, for ocular neovascularization conditions. Guangdong Zhongsheng will commit $9.75 million including up-front and milestone payments, and Sirnaomics will also be eligible for royalty sharing.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription